Isotechnika completes critical drug study, showing no cancer link

EDMONTON - Drug developer Isotechnika Inc. (TSX:ISA) says a critical study for its lead immunosuppressive drug showed no cancer link. During a two-year period, the drug failed to show carcinogenicity up to the highest doses tested in male and female rats....More